Relapsed multiple myeloma

Current Treatment Options in Oncology

Volumn 2, Issue 3, 2001, Pages 261-269

  Pandit, Sandeep ^a   Vesole, David H ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Arsenic Trioxide; Hematopoietic Stem Cell Transplant; Multiple Myeloma; Peripheral Blood Stem Cell Transplant; Thalidomide

Indexed keywords

ANGIOGENESIS INHIBITOR;

CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; PROGNOSIS; REVIEW; SALVAGE THERAPY; TUMOR RECURRENCE;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SALVAGE THERAPY;

EID: 0035383036     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-001-0040-6     Document Type: Article

References (40)

1. Bergsagel DE: The role of chemotherapy in the treatment of multiple myeloma. Baillieres Clin Haematol 1995, 8:783–794. DOI: 10.1016/S0950-3536(05)80259-8
2. Alexanian R, Barlogie B, Tucker S: VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990, 33:86–89. DOI: 10.1002/ajh.2830330203
3. Rajkumar SV, Hayman S, et al.: Thalidomide plus dexamethasone and thalidomide alone as first line treatment for newly diagnosed myeloma. Blood 2000, 96;722.
4. Pavlovsky S, Saslavsky J, Tezanos DM, et al.: A randomized trial of Melphalan and Prednisone versus melphalan, prednisone, cyclophosphamide, CCNU, and vincristine in untreated multiple myeloma. J Clin Oncol 1984, 2:836–840.
5. Divanen TM, for the Finnish Leukemia Group: Plateau phase in multiple myeloma: an analysis of long-term follow-up of 432 patients. Br J Haematol 1996, 92:834–839. DOI: 10.1046/j.1365-2141.1996.413952.x
6. Joshua DE, Brown RD, Gibson J: Multiple myeloma: why does the disease escape from plateau phase? Br J Haematol 1994, 88:667–671.
7. Belch A, Shelley W, Bergsagel D, et al.: A randomized trial of maintenance versus maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988, 57:94–99.
8. Westin J, Rodjer S, Turesson I, et al.: IFN alpha-2b versus no maintenance treatment during the plateau phase in multiple myeloma: a randomized study. Br J Haematol 1995, 89:561–568.
9. Browman GP, Bergsagel DE, Sicheri D, et al.: Randomized trial of IFN maintenance in multiple myeloma: a study of the Canada Clinical Trials group. J Clin Oncol 1995, 13:2354–2360.
10. Attal M, Harousseau JL, Stoppa AM, et al.: A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996, 335:91–97. DOI: 10.1056/NEJM199607113350204
11. Barlogie B, Jagannath S, Vesole DH, et al.: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997, 89:789–793. Nonrandomized study demonstrating the superiority of tandem transplant to conventional therapy.
12. Blade J, San Miguel JF, Fontanillas M, et al.: Survival of multiple myeloma patients who are potential candidates for early high-dose treatment intensification/ autotransplantation and who were conventionally treated. J Clin Oncol 1996, 14:2167–2173.
13. Barlogie B, Jagannath S, Desikan KR, et al.: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999, 93:55–65.
14. Attal MM, Harousseau JJ, Facon TT, et al.: Single versus double transplantation in myeloma: a prospective randomized trial of the Inter Groupe Francophone du Myeloma (IFM) [abstract]. Blood 2000, 96:2393.
15. Vescio R, Schiller G, Stewart AK, et al.: Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 1999, 93:1858–1868.
16. Cunningham D, Powles R, Malpas J, et al.: A randomized trial of maintenance interferon following highdose chemotherapy in multiple myeloma. Long term followup results. Br J Haematol 1998, 102:495–502. DOI: 10.1046/j.1365-2141.1998.00795.x
17. Desikan R, Fassas A, Munshi N, et al.: Intensive consolidation therapy after tandem transplants further improves the outcome of multiple myeloma patients [abstract]. Blood 2000, 96:730.
18. Gahrton G, Svensson H, Cavo M, et al.: Paper presented at VII International Multiple Myeloma Workshop. Allogeneic and syngeneic transplantation in multiple myeloma. September 1–5, 1999. Stockholm, Sweden.
19. Giralt S, Weber D, Aleman A, et al.: Non-myeloablative conditioning with Fludarabine/Melphalan (FM) for patients with multiple myeloma [abstract]. Blood 1999, 94:1549.
20. Lalancette M, Rezvani K, Szydlo R, et al.: Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk multiple myeloma: the EBMT experience [abstract]. Blood 2000, 96:872.
21. Paccagnella A, Chiarion-Sileni V, Soesan M, et al.:Second and third responses to the same induction regimen in relapsing patients with multiple myeloma. Cancer 1991, 68:975. DOI: 10.1002/1097-0142(19910901)68:5<975::AID-CNCR2820680511>3.0.CO;2-O
22. Barlogie B, Smith L, Alexanian R, et al.: Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984, 310:1353–1356. DOI: 10.1056/NEJM198405243102104
23. Dalton WS, Jove R: Drug resistance in multiple myeloma: approaches to circumvention. Semin Oncol 1999, 26(suppl):23–27.
24. Dhodapkar MV, Singh J, Mehta J, et al.: Antimyeloma activity of pamidronate in vivo. Br J Haematol 1998, 103:530–532. DOI: 10.1046/j.1365-2141.1998.00976.x
25. Berenson JR, Lichtenstein A, Porter L, et al.: Long-term pamidronate treatment of advanced multiple myeloma reduces skeletal events. J Clin Oncol 1998, 16:593–602. This is the a priori article proving the importance of bisphosphonates in multiple myeloma.
26. Vacca A, Ribatti D, Roncali L, et al.: Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994, 87:503–508.
27. Singhal S, Mehta J, Barlogie B, et al.: Anti-tumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565–1571. This key study proved the efficacy of thalidomide in refractory myeloma. DOI: 10.1056/NEJM199911183412102
28. Rajkumar SV, Timm MM, Go R, et al.: 2-Methoxyestradiol (2ME2) induces cell cycle arrest and apoptosis in myeloma and inhibits angiogenesis in the rat aortic ring assay: results of preclinical studies [abstract]. Blood 2000, 96:1557.
29. Vesole DH, Crowley JJ, Catchatourian R, et al.: Highdose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. J Clin Oncol 1999, 17:2173–2179. A cooperative group study showing superior outcome of autologous transplant as salvage therapy. Results were superior to historical control studies using conventional treatments.
30. Rajkumar SV, Fonseca R, Gertz MA, et al.: Autologous stem cell transplantation for relapsed and primary multiple myeloma. Bone Marrow Transplant 1999, 23:1267–1272. DOI: 10.1038/sj.bmt.1701805
31. Tricot G, Jagannath S, Vesole DH, et al.: Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 1995, 16:7–11.
32. Morris TCM, Svebsson H, Bjorkstrand B, et al.: If double PBSC transplants have a role in myeloma when are they best performed? An EBMT Registry study [abstract]. Blood 2000, 96:3447.
33. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al.:Donor leukocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000, 18:3031–3037. The use of donor leukocyte infusions can induce a graft-versusmyeloma effect after relapse from allogeneic transplant.
34. Alyea EP, Soiffer RJ, Ritz J, et al.: Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998, 91:3671–3680.
35. Stinchcombe TE, Mitchell BS, Depcik-Smith N, et al.:PS-341 is active in multiple myeloma: preliminary report of a phase I trial of the Proteasome inhibitor PS-341 in patients with hematologic malignancies [abstract]. Blood 2000, 98:2219.
36. Hussein MA, Karam MA, McLain DA, et al.: Biologic and clinical evaluation of Rituxan in the management of newly diagnosed multiple myeloma [abstract]. Blood 1999, 94:1400.
37. Bataille R, Barlogie B, Lu ZY, et al.: Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995, 86:685–691.
38. Munshi N, Desikan R, Zangari M, et al.: Marked antitumor effect of arsenic trioxide in high risk refractory multiple myeloma [abstract]. Blood 1999, 96:541.
39. Vesole DH, Kornbluth J, Jagannath S, et al.: Biological response modifiers in refractory multiple myeloma: lack of clinical efficacy of recombinant human interleukin-4 and all-trans retinoic acid (ATRA). Blood 1993, 82:263a.
40. Trivedi E, Al-Katib A, Murgo B, et al.: Phase II clinical evaluation of Bryostatin-1 in patients with relapsed multiple myeloma [abstract]. Blood 1999, 96:4635.